Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Biocon Limited
  6. News
  7. Summary
    BIOCON   INE376G01013


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Indian pharma firms go local seeking to end reliance on China

02/23/2021 | 06:42am EDT
FILE PHOTO: The logo of Sun Pharma on the facade of its corporate office in Mumbai

NEW DELHI (Reuters) - Indian drug companies are looking to local makers of so-called active pharmaceutical ingredients (API) or trying to make them in-house in a bid to end their reliance on China as ties between the two countries soured after a deadly border clash last June.

Though India is known as the pharmacy of the world for its massive production capacities of both generic drugs and vaccines, China accounted for half of its API needs in 2019 from nearly nothing three decades ago, industry data shows.

Executives at India's Cadila Healthcare, Cipla, Sun Pharmaceutical and ?Biocon said on Tuesday they were aggressively working on reducing the dependence on the richer rival for raw materials.

Disruption to supplies from China due to the COVID-19 pandemic was also a major factor, they said, as early last year many of them had to scramble for ingredients to make important drugs sold worldwide.

"Because of the anti-China sentiment ... most of the companies are working towards de-risking themselves in terms of making it clear that their supply chain linkages with China are limited," Gaurav Suchak, supply head of Cadila, told the BioAsia conference organised by the southern state of Telangana.

"For the critical API molecules, the idea is to go for a backward integration where you are in control of that pie which is going to make the most impact on your business, and also to make sure that the entire value chain is secure."

Companies are also eyeing reliable local vendors who can promise consistency and competitive prices, he said.

Cipla's supply chief Swapn Malpani said it had launched an "API re-imagination" programme to possibly expand its own manufacturing capacities using recent government incentives such as production subsidies, apart from working with local suppliers.

Biocon's supply head Prasad Deshpande said the company had a target on "how much percent of revenue is independent of China".

"We are happy to say that by the last quarter, we were almost 50% completely independent of China," Deshpande said. "That does not mean we will not source from China, but we are not dependent on China anymore."

But he also said India would have to improve its infrastructure and accelerate approval processes to take on the scale and speed of China.

(Reporting by Krishna N. Das; editing by David Evans)

By Krishna N. Das

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
BIOCON LIMITED -1.31% 347.65 Delayed Quote.-25.30%
CADILA HEALTHCARE LIMITED -0.28% 544.1 Delayed Quote.14.13%
CIPLA LIMITED -0.24% 911.35 Delayed Quote.11.15%
SUN PHARMACEUTICAL INDUSTRIES LTD. -0.15% 841.3 Delayed Quote.42.03%
All news about BIOCON LIMITED
10/05BIOCON : expands its Generic Formulations portfolio with the launch of Everolimus tablets ..
10/04BIOCON : Launches Cancer Treatment Drug Everolimus in US
10/03Biocon Ltd Expands Its Generic Formulations Portfolio with the Launch of Everolimus Tab..
09/26BIOCON : Insulin Manufacturing Unit in Malaysia Gets Six Observations from US FDA
09/22India's Serum Institute to invest $68 mln in UK vaccine maker Oxford Biomedica
09/17Biocon unit plans 15% stake sale to Serum Institute for access to vaccines
09/16BIOCON : Biologics Forms Strategic Alliance with Serum Institute Life Sciences
09/07BIOCON : Signs Settlement Agreement with US-Based Celgene in Cancer-Treatment Drug Patent ..
07/29Biocon Biologics and Viatris Inc. Receive Approval for First Interchangeable Biosimilar..
07/26BIOCON : Arm Gets License from US Company for COVID-19 Monoclonal Antibody
More news
Sales 2022 83 477 M 1 113 M 1 113 M
Net income 2022 8 039 M 107 M 107 M
Net Debt 2022 28 796 M 384 M 384 M
P/E ratio 2022 51,2x
Yield 2022 0,30%
Capitalization 414 B 5 513 M 5 512 M
EV / Sales 2022 5,30x
EV / Sales 2023 4,22x
Nbr of Employees 13 500
Free-Float 34,7%
Duration : Period :
Biocon Limited Technical Analysis Chart | BIOCON | INE376G01013 | MarketScreener
Technical analysis trends BIOCON LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 18
Last Close Price 347,65 INR
Average target price 391,17 INR
Spread / Average Target 12,5%
EPS Revisions
Managers and Directors
Siddharth Mittal Chief Executive Officer, Director & MD
Indranil Sen Chief Financial Officer
Kiran Mazumdar-Shaw Executive Chairman
Manoj Kumar Pananchukunnath Head-Regulatory Sciences, Research & Development
Sandeep Nilkanth Athalye Head-Clinical Development & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BIOCON LIMITED-25.30%5 513
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820